Urate-Lowering Therapy May Reduce Type 2 Diabetes Risk in Patients With Gout
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Researchers investigated the association between gout, urate-lowering therapy use, and the risk of developing type 2 diabetes.
Data suggest that vitamin C supplementation should not be recommended to lower plasma urate.
Arhalofenate, a novel uricosuric investigational drug, appears to be well-tolerated and significantly decreased the number of gout flares compared to allopurinol. If approved, it would be the first urate-lowering anti-flare therapy for gout.
The presence of tophi in people with gout was associated with increased risk for cardiovascular disease.